Home » Stocks » RLMD

Relmada Therapeutics, Inc. (RLMD)

Stock Price: $35.73 USD 0.24 (0.68%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 580.31M
Revenue (ttm) n/a
Net Income (ttm) -43.22M
Shares Out 16.04M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $35.73
Previous Close $35.49
Change ($) 0.24
Change (%) 0.68%
Day's Open 35.17
Day's Range 34.70 - 36.58
Day's Volume 61,976
52-Week Range 23.78 - 50.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.

PRNewsWire - 1 month ago

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...

Investopedia - 4 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, PRGO, SNY, SUPN, TAK
PRNewsWire - 4 months ago

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

The Motley Fool - 6 months ago

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: DRRX, NLTX
PRNewsWire - 7 months ago

NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases...

PRNewsWire - 7 months ago

NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases...

The Motley Fool - 8 months ago

Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?

Investopedia - 10 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.

Other stocks mentioned: GILD, TCNNF
Seeking Alpha - 11 months ago

Relmada Therapeutics: A Promising Depression Focused Player For 2020

Investopedia - 1 year ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1.

Other stocks mentioned: TCNNF
Market Watch - 1 year ago

Relmada Therapeutics Inc. shares RLMD, +141.79% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression.

About RLMD

Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesi... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2004
CEO
Sergio Traversa
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
RLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price forecast is 62.83, which is an increase of 75.85% from the latest price.

Price Target
$62.83
(75.85% upside)
Analyst Consensus: Strong Buy